$Novo-Nordisk A/S(NVO)$  (Source: Barchart.com) 

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Barchart Technical Indicators:

100% technical buy signals

45.50+Weighted Alpha

34.83% gain in the last year

Trend Seeker buy signal

Above its 20, 50 and 100 day moving averages

10 new highs and up 10.26% in the last month

Relative Strength Index 76.12%

Recently traded at $138.80 with 50 day moving average of $123.01

Fundamental Factors:

Market Cap $308 billion

P/E 40.58

Dividend yield .60%

Revenue expected to increase 27.40% this year and another 13.00% next year

Earnings estimated to increase 20.10 this year, an additional 22.00% next year and continue to compound again at an annual rate of 2.72% for the next 5 years

Analysts and Investor Sentiment:

Wall Street analysts have 3 strong buy and 2 hold opinions in place on this stock

Analysts have price targets from $119.22 to $ 146.05 with an average of $132.58 which is down 4.44% from its present price

The individual investors following the stock on Motley Fool voted 710 to 24 for the stock to beat the market with more experienced investors voting 168 to 30 for the same result

47,020 investors are monitoring this stock on Seeking Alpha